Cost‐Effectiveness of Automated Insulin Delivery Systems in Paediatrics, T1D and T2D Adults Across Four Nordic Countries
Authors' conclusion
AID therapy consistently projected reduced diabetes-related complications while remaining cost-effective across a broad spectrum of diabetes patient profiles in the Nordic region. These findings strengthen the case towards widespread integration of AID technology into national diabetes care frameworks.
Study context
- Population
- Children with T1D, adults with T1D and insulin-treated individuals with T2D in Denmark, Finland, Norway and Sweden; five modelled profiles: T1D paediatrics (T1D-Paed), T1D-Adult (high baseline HbA1c), T1D-AdultRWE (lower baseline HbA1c), T2D adults (T2D-Adult), T2D-Elder5 modelled profiles
- Comparison
- Automated insulin delivery (AID) vs multiple daily injections (MDI) + CGM
- Outcome
- Long-term cost-effectiveness (ICERs vs willingness-to-pay thresholds)
- Follow-up
- Up to 50 years
Methodological detailsIQVIA Core Diabetes Model, healthcare system perspective, horizons up to 50 years, 3% annual discounting, sensitivity analyses
- IQVIA Core Diabetes Model
- Healthcare system perspective
- Horizons up to 50 years
- 3% annual discounting
- Sensitivity analyses
Main finding
As reported in the abstract
Cost-effectiveness · lifetime
Lifetime cost savings with AID
€1435 to €26 259
Further findings
Diabetes-related complications per 100 individuals, T1D-Adult
Diabetes-related complications per 100 individuals, T1D-Adult
- Reduction in diabetes-related complications with AID in all groups
Original publication
Cost‐Effectiveness of Automated Insulin Delivery Systems in Paediatrics, T1D and T2D Adults Across Four Nordic Countries. Diabetes Obes Metab. Published 19 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →